Cara Therapeutics Inc. (NASDAQ:CARA)’s share price traded up 4.5% during trading on Wednesday . The company traded as high as $6.09 and last traded at $6.04, with a volume of 343,507 shares. The stock had previously closed at $5.78.

A number of equities analysts have commented on the stock. Zacks Investment Research cut shares of Cara Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, July 11th. Canaccord Genuity reissued a “buy” rating and issued a $30.00 price objective on shares of Cara Therapeutics in a research note on Friday, May 6th. Needham & Company LLC reaffirmed a “buy” rating on shares of Cara Therapeutics in a research note on Friday, May 6th. Piper Jaffray Cos. reaffirmed an “overweight” rating and set a $23.00 price target on shares of Cara Therapeutics in a research note on Saturday, April 23rd. Finally, Cantor Fitzgerald reaffirmed a “buy” rating on shares of Cara Therapeutics in a research note on Wednesday, April 20th. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $21.21.

The stock’s 50 day moving average is $5.24 and its 200-day moving average is $6.34. The company’s market capitalization is $165.87 million.

Cara Therapeutics (NASDAQ:CARA) last posted its quarterly earnings data on Thursday, May 5th. The biopharmaceutical company reported ($0.39) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.40) by $0.01. During the same quarter in the prior year, the company posted ($0.21) earnings per share. The company had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.03 million. The business’s revenue was down 98.6% on a year-over-year basis. Equities analysts anticipate that Cara Therapeutics Inc. will post ($1.72) earnings per share for the current year.

An institutional investor recently raised its position in Cara Therapeutics stock. GSA Capital Partners LLP raised its position in shares of Cara Therapeutics Inc. (NASDAQ:CARA) by 29.5% during the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 91,073 shares of the biopharmaceutical company’s stock after buying an additional 20,754 shares during the period. GSA Capital Partners LLP owned approximately 0.33% of Cara Therapeutics worth $1,535,000 as of its most recent SEC filing.

Cara Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by focusing on kappa opioid receptors. The Company is engaged in developing product candidates that focus on the body’s peripheral nervous system.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.